A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients

[1]  P. Dönnes,et al.  Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. , 2019, Seminars in arthritis and rheumatism.

[2]  X. Montalban,et al.  Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study , 2019, Journal of Neuroimmunology.

[3]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[4]  Shi-Ying Huang,et al.  A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody. , 2018, Current drug metabolism.

[5]  B. Becher,et al.  T cells in patients with narcolepsy target self-antigens of hypocretin neurons , 2018, Nature.

[6]  F. Piehl,et al.  Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies , 2018, Multiple sclerosis.

[7]  J. Greenbaum,et al.  Improved methods for predicting peptide binding affinity to MHC class II molecules , 2018, Immunology.

[8]  X. Mariette,et al.  Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors , 2017, Front. Immunol..

[9]  G. Wolbink,et al.  UvA-DARE ( Digital Academic Repository ) Immunogenicity of therapeutic antibodies , 2017 .

[10]  X. Montalban,et al.  Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results , 2017, PloS one.

[11]  Ryan Ramanujam,et al.  Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis , 2016, PloS one.

[12]  G. Murdaca,et al.  Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? , 2016, Expert opinion on drug safety.

[13]  Steven H. Kleinstein,et al.  Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data , 2015, Bioinform..

[14]  E. Havrdová,et al.  Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium , 2015, Clinical and experimental immunology.

[15]  L. Jensen,et al.  Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation* , 2015, Molecular & Cellular Proteomics.

[16]  Xavier Montalban,et al.  Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles , 2014, Neurology: Neuroimmunology & Neuroinflamm.

[17]  John Sidney,et al.  Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes , 2014, BCB.

[18]  V. Shaygannejad,et al.  Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon , 2013, Journal of Korean medical science.

[19]  Yamei Yu,et al.  How Natalizumab Binds and Antagonizes α4 Integrins* , 2013, The Journal of Biological Chemistry.

[20]  David H. Miller,et al.  Natalizumab Therapy for Multiple Sclerosis , 2013, Neurotherapeutics.

[21]  Steven H. Kleinstein,et al.  Quantifying selection in high-throughput Immunoglobulin sequencing data sets , 2012, Nucleic acids research.

[22]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[23]  M. Mann,et al.  Andromeda: a peptide search engine integrated into the MaxQuant environment. , 2011, Journal of proteome research.

[24]  R. Dubridge,et al.  The immunogenicity of humanized and fully human antibodies , 2010, mAbs.

[25]  Michel C Nussenzweig,et al.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.

[26]  D. Miller,et al.  The incidence and significance of anti-natalizumab antibodies , 2007, Neurology.

[27]  Jérôme Lane,et al.  IMGT®, the international ImMunoGeneTics information system® , 2004, Nucleic Acids Res..

[28]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[29]  A. Vagin,et al.  MOLREP: an Automated Program for Molecular Replacement , 1997 .

[30]  L M Amzel,et al.  Anti‐idiotypic antibodies: biological function and structural studies , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  C. Milstein,et al.  Kinetic maturation of an immune response , 1991, Nature.

[32]  J. Borst,et al.  Characterization of monoclonal antibodies against cell surface molecules associated with cytotoxic activity of natural and activated killer cells and cloned CTL lines. , 1983, Hybridoma.

[33]  F. Bach,et al.  Detection of a novel human class II HLA antigen , 1983, Nature.